Arsenic Trioxide

CHEMBL5483015 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
197.8 g/mol
LogP
Phase
4

A chemotherapy agent that induces differentiation and programmed cell death in cancer cells, particularly in acute promyelocytic leukemia. It has transformed outcomes in this once-fatal leukemia.

分子量

197.8410 g/mol

TPSA

3.00 Ų

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=[As][As+](=O)[O-]

InChI

InChI=1S/As2O3/c3-1-2(4)5

Molecular Formula

As2O3

HBD / HBA

- / 3

可旋转键数

0

重原子数

5

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A chemotherapy agent that induces differentiation and programmed cell death in cancer cells, particularly in acute promyelocytic leukemia. It has transformed outcomes in this once-fatal leukemia.

Yes, Arsenic Trioxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5483015. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 14888. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.